Brief: Immunome - Enters Amendment No. 4 To License Agreement With Bristol-Myers Squibb Company On Oct 2, 2026
05/10/2026 13:39
BRIEF-Immunome - Enters Amendment No. 4 To License Agreement With Bristol-Myers Squibb Company On Oct 2, 2026 Oct 5 (Reuters) - Immunome, Inc. IMNM.O:
IMMUNOME - ENTERS AMENDMENT NO. 4 TO LICENSE AGREEMENT WITH BRISTOL-MYERS SQUIBB COMPANY ON OCT 2, 2026 - SEC FILING
IMMUNOME - AMENDMENT REMOVES CO'S MILESTONE & ROYALTY PAYMENT OBLIGATIONS AND ASSIGNS PATENT RIGHTS RELATED TO VAREGACESTAT, AL101 - SEC FILING
IMMUNOME - PAYS BMS $20 MILLION CASH AND ISSUES 4,425,487 SHARES AS AMENDMENT CONSIDERATION - SEC FILING
IMMUNOME - HAS NO FURTHER PAYMENT OBLIGATIONS TO BMS UNDER LICENSE AGREEMENT - SEC FILING
Source text: [ID:n0001193125-26-413217]
Further company coverage: IMNM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immunome
See all newsBrief: Immunome - Enters Amendment No. 4 To License Agreement With Bristol-Myers Squibb Company On Oct 2, 2026
US STOCKS ON THE MOVE-Cardinal Health, nVent, Acuity
U.S. STOCKS ON THE MOVE-Cardinal Health, Fervo Energy, Rocket Lab
U.S. STOCKS ON THE MOVE-Progress Software, Vicor Corp, Accenture
Immunome climbs as Stifel initiates coverage